Clinical trials: Clinical Trial, Phase I
Neoplasms
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
The primary objective of this trial is to determine the maximum tolerated dose (MTD)/optimal biological dose (OBD) of BI 905681 given as an intravenous infusion and to determine the recommended dose and dosing schedule for…
- Trial name
- NCT04147247
- Testing
- BI 905681
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
The main objective of the dose-escalation part of the trial is to determine the safety and tolerability, and to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D) of BI 754091 on the basis of patients…
- Trial name
- NCT02952248
- Testing
- BI 754091
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in…
- Trial name
- NCT05421338
- Testing
- BI 456906 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetic Foot Ulcer
Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers
This is a phase I open-label study to evaluate the safety of ALLO-ASC-DFU in diabetic foot ulcers patients. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells.
- Trial name
- NCT02394886
- Testing
- ALLO-ASC-DFU
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Anterogen Co., Ltd.
Advanced Tumors
Study of BMS-986158 in Subjects With Select Advanced Cancers
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
- Trial name
- BET (NCT02419417)
- Testing
- BMS-986158, Nivolumab
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
Drug Drug Interaction
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects
- Trial name
- NCT05574374
- Testing
- DWP14012, DWC202202, DWC202203
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Relapsed/Refractory Multiple Myeloma
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.
- Trial name
- NCT06049290
- Testing
- LBL-034 for Injection
- Where
- 21 sites in China
- Volunteers
- 342 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Leukemia, Myeloid, Acute
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. In addition, acute myeloid leukemia patients who are in complete remission with high risk to relapse…
- Trial name
- NCT01690624
- Testing
- BI 836858
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced…
- Trial name
- NCT07083323
- Testing
- HY05350 for injection
- Where
- China
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Pruritus
A Study of SHR4010 in Patients With Hemodialysis
The study is being conducted to evaluate the safety and pharmacokinetics of SHR0410 in patients with hemodialysis.
- Trial name
- NCT04099927
- Testing
- SHR0410
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Total Laryngectomy
Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis
The purpose of this study is to investigate long-term clinical feasibility of a new voice prosthesis and insertion system Provox Vega 20 with SmartInserter) for voice rehabilitation after total laryngectomy.
- Trial name
- NCT00661570
- Testing
- Provox Vega voice prosthesis (20 Fr)
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Atos Medical AB
Respiratory Syncytial Virus Infections
A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants
The purpose of this clinical trial is to learn about the interaction of sisunatovir with four medications (midazolam, itraconazole, rifampicin, and verapamil).
- Trial name
- NCT03782662
- Testing
- Itraconazole, Verapamil, Rifampicin
- Where
- United Kingdom
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Pfizer
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it…
- Trial name
- NCT03666273
- Testing
- Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bayer
Healthy
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway.
- Trial name
- NCT04972188
- Testing
- ZYIL1 Capsule
- Where
- India
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
HIV Infections
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
To determine the physiological and immunological responses in healthy HIV seronegative adult volunteers vaccinated with a) the HIVAC-1e (vaccinia-HIV) vaccine expressing the envelope glycoproteins of HIV and b) the Wyeth smallpox…
- Trial name
- NCT00002261
- Testing
- Smallpox Vaccine, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
COVID-19
Study of HS-10517 in Chinese Adult Participants
A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.
- Trial name
- NCT05779579
- Testing
- HS-10517 Dose 1, HS-10517 Dose 2, HS-10517 Dose 3
- Where
- China
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-muscle Invasive Bladder Cancer
A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer
This study evaluates the tolerability and preliminary anti-tumour effect of alpha1H in adults with non-muscle invasive bladder cancer, who are awaiting transurethral surgery.
- Trial name
- NCT03560479
- Testing
- alpha1H, 7.4 mg/mL, alpha1H, 37 mg/mL, alpha1H, 74 mg/mL
- Where
- Czechia
- Volunteers
- 52 people
- Sponsor
- Hamlet Pharma AB
Healthy
A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults
The objectives of this study are to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of multiple doses of ABT-436 in healthy adults.
- Trial name
- NCT01050127
- Testing
- ABT-436
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Abbott
Diphtheria, Tetanus
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults
This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT05952596
- Testing
- DTaP-HepB-IPV-Hib vaccine
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- LG Chem
Drug-drug Interaction,SHR3680
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of digoxin, Rosuvastatin calcium and metformin hydrochloride.
- Trial name
- NCT04621669
- Testing
- SHR3680, digoxin, Rosuvastatin calcium
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.